Bombardier Challenger 350 Jet Most Delivered in Category for Seventh Consecutive Year, Company Also Ends 2020 With Highest Total Market Share in Fourth Quarter

MONTREAL, Feb. 26, 2021 (GLOBE NEWSWIRE) — Bombardier announced today that its best–selling Challenger 350 aircraft was the most–delivered medium category business jet in 2020, making it the category leader for a seventh consecutive year. As detailed in the General Aviation Manufacturers Association's (GAMA) annual shipment and billings report released February 24, the company also outpaced competitors by delivering 44 aircraft in the fourth quarter of 2020. This accomplishment was driven by a record 16 Global 7500 business jet deliveries in that timeframe.

Bombardier's comprehensive family of business jets firmly positions it to respond to the growing interest in private aviation and the enhanced safety they provide during these exceptional times.

As more people seek to avoid crowds and interest in fractional and air charter increases, the best–selling Challenger 350 aircraft is there to take passengers where they need to be, and it continues to surpass expectations while doing so.

In 2020, Bombardier announced a firm order for 10 Challenger 350 aircraft in a transaction valued at $267 million U.S. and also marked the 350th delivery of the Challenger 350 business jet, a milestone reached after only seven years in service. The best–selling Challenger 350 aircraft now features an expanded selection of sophisticated and contemporary interior design schemes, high–speed Viasat Ka–band connectivity and a refreshed cabin management system, inspired by the industry's flagship Global 7500 business jet.

In addition to the Challenger 350 aircraft, Bombardier's Challenger 650 business jet is a masterful expression of high–end craftsmanship and functionality. With its ideal combination of range, speed and field performance capabilities, the Challenger 650 aircraft is perfectly suited for both private and specialized missions, including medevac. The Challenger 650 aircraft is in service with many governments worldwide for various special missions.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Notes to Editors
Visit the Bombardier Business Aircraft website for more information on our industry–leading products and services.

Follow @Bombardierjets on Twitter to receive the latest news and updates from Bombardier Aviation.

To receive our press releases, please visit the RSS Feed section.

Bombardier, Challenger, Challenger 350, Challenger 650 and Global 7500 are either unregistered or registered trademarks of Bombardier Inc. or its subsidiaries.

For Information
Anna Cristofaro
Bombardier
+ 1 514–855–8678
anna.cristofaro@aero.bombardier.com


GLOBENEWSWIRE (Distribution ID 8160836)

Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

"' EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in Supplemental Calcium Usage ""

"' Oral Human Parathyroid Hormone (1–34) Has the Potential to Have a Major Impact on Compliance, Adherence, Therapeutic Impact and Quality of Life for Patients ""

BOSTON and JERUSALEM, Feb. 25, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today the publication of the results of its previously completed Phase 2a study of EB612 in the Journal of Bone and Mineral Research. The article, titled "Safety and Efficacy of Oral Human Parathyroid Hormone (1–34) in Hypoparathyroidism: An Open–Label Study," discussed the results of the four–month study in which EB612 was evaluated in 2015 as an adjunct to standard calcium and vitamin D supplement treatment in patients with hypoparathyroidism (HypoPT). EB612, an oral human parathyroid hormone (1–34) (PTH), has received Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of HypoPT.

The Phase 2a study demonstrated the safety and tolerability of EB612 administered four times daily for 16 weeks to patients with HypoPT. The study achieved its primary and secondary endpoints, including a reduction in calcium supplements, reductions in serum phosphate and 24–hour urine calcium excretion, maintenance of albumin–adjusted serum calcium (ACa) within the reference range, and an improvement in quality of life. Specific results of this trial included:

  • A significant reduction of 42% (p=0.001) from baseline in median calcium supplement use;
  • Maintenance of median ACa levels above the lower target level for HypoPT patients (>7.5 mg/dL) throughout the study;
  • A rapid decline of 23% (p=0.0003) in median serum phosphate levels 2 hours following the first dose that was maintained within the normal range for the duration of the study;
  • A notable median decrease of 21% (p=0.07) in 24–hour urine calcium excretion between the first and last treatment days; and
  • An increase in quality of life score of 5% (p=0.03) from baseline by the end of the treatment period.

In this study, patients were titrated up to a maximum of 12 EB612 0.75 mg tablets a day (total daily dose of 9 mg) by the investigator, according to each subject's ACa, and supplement treatment regimen. Of the 19 enrolled subjects, 17 completed the trial (of which 15 were per protocol). No drug–related serious adverse events were reported and most of the adverse events were not considered study drug–related.

"The publication of our Phase 2a EB612 study results in this leading peer–reviewed journal support our HypoPT development program and the value of our platform technology. The availability of an oral PTH is expected to improve compliance, as well as therapeutic impact and may offer patients with HypoPT a much–needed alternative to the currently available parathyroid hormone replacement therapy options which are administered via daily injections. We are currently working on improved formulations of EB612 and the design of the next clinical trial which we expect to initiate in 2022," stated Entera CEO Spiros Jamas. "In addition, through the use of our previously announced at–the–market equity program, we have continued to strengthen our balance sheet in the first quarter of 2021, and we are now funded into the fourth quarter of 2021."

The full peer–reviewed publication will be available on Entera's website once the final article is released for publication and can be found here.

About Hypoparathyroidism

Hypoparathyroidism (HypoPT) is a rare condition in which the body produces insufficient amounts of parathyroid hormone. Individuals with HypoPT typically exhibit abnormally low levels of calcium in the blood (hypocalcemia), and high levels of phosphate in the blood (hyperphosphatemia). They also develop increased urine calcium (hypercalciuria). HypoPT is estimated to affect approximately 77,000 individuals in the United States. Historically, the treatments for HypoPT have been calcium supplements and active vitamin D (calcitriol or alfacalcidol). Phosphate binders that inhibit phosphate absorption and thiazide diuretics that reduce urine calcium are occasionally added. It is often difficult to titrate the dose of both calcium supplements and active vitamin D to reduce symptoms of hypocalcemia without producing increased urine calcium or hypercalcemia with tissue calcification during chronic use, which can result in kidney injury and significant healthcare costs. Moreover, the high doses of calcium supplements may produce stomach and gastrointestinal symptoms as well as other symptoms that negatively affect a patient's quality of life. A once–daily, injectable form of parathyroid hormone has been approved by the FDA and EMA for the treatment of hypocalcemia in patients with HypoPT.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the interim data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the results of formulation development work on EB612 the impact on future clinical trials, the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Quarterly Report on Form 6–K for the quarter ended September 30, 2020, filed with the SEC in the fourth quarter of 2020. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.


GLOBENEWSWIRE (Distribution ID 8159069)

FXCM Stock Baskets Traders Go Big on BIOTECH and ESPORTS in January

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, Feb. 25, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC (“FXCM Group” or “FXCM”), the leading international provider of online foreign exchange trading, CFD trading and related services, is today releasing the volume increases for the month of January in its proprietary stock basket product line.

FXCM's stock basket products combine the shares of multiple companies from one sector into a single tradeable instrument. This allows customers to speculate on sectors as a whole instead of having to select a single company. FXCM now boosts a portfolio of thirteen stock baskets.

For the 5th month in a row, FAANG continues to be the most popular traded stock basket at FXCM, as the Cannabis and Chinese Technology baskets were the best performing sectors.

On the back of the news surrounding global vaccinations, the Biotechnology basket along with the Esports and Gaming baskets have seen the biggest comparative monthly jumps in FXCM client interest in early 2021 vs December 2020.

The list of companies and weightings is available on FXCM's stock basket website (https://www.fxcm.com/markets/stock–baskets/)

Volume Rank Sector Symbol Jan Price Change1 Monthly Change in FXCM Volume2
1 Big US Tech FAANG –0.50% 55.32%
2 Biotech BIOTECH 1.90% 364.42%
3 Chinese E–Commerce CHN.ECOMM 1.98% –29.87%
4 Cannabis CANNABIS 35.02% 42.40%
5 Chinese Tech CHN.TECH 24.80% 75.26%
6 Esports & Gaming ESPORTS –2.87% 628.38%
7 Airlines AIRLINES –2.96% –33.29%
8 US–Ecommerce US.ECOMM 7.20% 71.56%
9 Travel and Hospitality TRAVEL –7.29% 230.10%
10 US Banks US.BANKS 0.56% –74.36%
11 Casinos CASINOS –6.04% 67.12%
12 Work From Home WFH 4.18% –17.67%
13 US Automotive US.AUTO 8.93% 76.95%

Past Performance is not an indicator of future results.
1 Price change figures are calculated using FXCM's opening bid price from 4 January 2021 and the closing price from 29 January 2021.
2 Percent change month–over–month (December 2020 vs. January 2021) is derived from FXCM client volume data.

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

76.31% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

The vast majority of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8159119)

FXCM Group Reports Monthly Execution Data

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, Feb. 24, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC (“FXCM Group” or "FXCM"), a leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related services, today released execution data for January 2021. To view execution data including historical spreads, execution speeds and historical price improvement data click here: https://www.fxcm.com/uk/about–fxcm/execution–transparency/ .

January 2021 All Instruments Highlights:*

  • 62.1% of orders executed at price1
  • 24.8% of orders executed with positive slippage2
  • 13.1% of orders executed with negative slippage3
  • Average execution speed 32 milliseconds4

Highlighted Instruments January 2021:

Instrument Active
Trader
Peak
Spread5
Active
Trader
Non–Peak
Spread
5
Active Trader
Effective
Spread
6
At Price
Orders
Positive
Slippage
Negative
Slippage
BTC/USD 61.0 61.2 53.2 68.5% 19.9% 11.7%
ETH/USD 2.7 2.5 1.9 77.6% 10.8% 11.6%
LTC/USD 0.5 0.5 0.4 85.3% 7.4% 7.4%
XAU/USD 0.4 0.4 0.4 52.3% 32.4% 15.3%
SPX500 0.4 0.4 0.4 49.5% 30.6% 19.9%
NAS100 1.0 1.1 1.1 39.4% 37.8% 22.8%
EUR/USD 0.1 0.3 0.2 69.4% 21.1% 9.6%
GBP/USD 0.3 0.9 0.4 67.5% 22.3% 10.3%
AUD/USD 0.2 0.4 0.3 73.6% 18.7% 7.7%

For more information and to open a live account, traders can contact an FXCM specialist 24 hours a day, 5 days a week.

*These highlights come from orders that executed through FXCM Group from 1 January 2021, to 31 January 2021. Data excludes certain types of non–direct clients.

1Percentage of executed client trades# in January 2021, which were executed at the price clients requested.
2Percentage of executed client trades# in January 2021, which were executed at a more favorable price than the price clients requested.
3Percentage of executed client trades# in January 2021, which were executed at a less favorable price than the price clients requested.
4This defines the amount of time between when we receive the order until execution. This excludes internet latency and post trade booking.
5This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 January 2021, to 31 January 2021. The data reflects average spreads made available to FXCM clients during all trading hours.
6This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 January 2021, to 31 January 2021. The data reflects the spread at which trades were executed by FXCM clients during all trading hours.
#Client trades here cover stop, limit, "at market", and entry orders. Certain non–direct clients are excluded from the data. Limit and limit entry orders would only execute at the requested price or better and cannot receive negative slippage. Price improvements are subject to available liquidity.

About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

76.31% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Between 74–89% of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8158975)

FXCM Group Reports Monthly Execution Data

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, Feb. 24, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC (“FXCM Group” or "FXCM"), a leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related services, today released execution data for January 2021. To view execution data including historical spreads, execution speeds and historical price improvement data click here: https://www.fxcm.com/uk/about–fxcm/execution–transparency/ .

January 2021 All Instruments Highlights:*

  • 62.1% of orders executed at price1
  • 24.8% of orders executed with positive slippage2
  • 13.1% of orders executed with negative slippage3
  • Average execution speed 32 milliseconds4

Highlighted Instruments January 2021:

Instrument Active
Trader
Peak
Spread5
Active
Trader
Non–Peak
Spread
5
Active Trader
Effective
Spread
6
At Price
Orders
Positive
Slippage
Negative
Slippage
BTC/USD 61.0 61.2 53.2 68.5% 19.9% 11.7%
ETH/USD 2.7 2.5 1.9 77.6% 10.8% 11.6%
LTC/USD 0.5 0.5 0.4 85.3% 7.4% 7.4%
XAU/USD 0.4 0.4 0.4 52.3% 32.4% 15.3%
SPX500 0.4 0.4 0.4 49.5% 30.6% 19.9%
NAS100 1.0 1.1 1.1 39.4% 37.8% 22.8%
EUR/USD 0.1 0.3 0.2 69.4% 21.1% 9.6%
GBP/USD 0.3 0.9 0.4 67.5% 22.3% 10.3%
AUD/USD 0.2 0.4 0.3 73.6% 18.7% 7.7%

For more information and to open a live account, traders can contact an FXCM specialist 24 hours a day, 5 days a week.

*These highlights come from orders that executed through FXCM Group from 1 January 2021, to 31 January 2021. Data excludes certain types of non–direct clients.

1Percentage of executed client trades# in January 2021, which were executed at the price clients requested.
2Percentage of executed client trades# in January 2021, which were executed at a more favorable price than the price clients requested.
3Percentage of executed client trades# in January 2021, which were executed at a less favorable price than the price clients requested.
4This defines the amount of time between when we receive the order until execution. This excludes internet latency and post trade booking.
5This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 January 2021, to 31 January 2021. The data reflects average spreads made available to FXCM clients during all trading hours.
6This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 January 2021, to 31 January 2021. The data reflects the spread at which trades were executed by FXCM clients during all trading hours.
#Client trades here cover stop, limit, "at market", and entry orders. Certain non–direct clients are excluded from the data. Limit and limit entry orders would only execute at the requested price or better and cannot receive negative slippage. Price improvements are subject to available liquidity.

About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

76.31% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Between 74–89% of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8158975)

JETEX MAKES FLYING WITH A REDUCED CARBON FOOTPRINT POSSIBLE

Dubai, United Arab Emirates, Feb. 24, 2021 (GLOBE NEWSWIRE) — Jetex customers are now able to choose to fly with a reduced carbon footprint from six key global locations following an agreement with Shell. This demonstrates how general aviation service providers can support the International Air Transport Association (IATA) and its commitment to reducing the industry's carbon emissions by 50% by 2050.

Jetex, an award–winning global leader in executive aviation, is fully aware of its responsibility towards the natural environment and to future generations, and pursues a comprehensive environmental strategy.

In today's world, private aviation is a vital global catalyst for growth, providing access to markets, supporting jobs and promoting travel recovery. In addition to its many positive economic effects, though, air transport contributes to the production of carbon emissions. In response, Jetex is working with Shell to offer customers an option to offset the carbon emissions of their air travel. Offsets represent an immediate measure that can be deployed at scale by compensating for CO2 emissions.

Every day, more than 200 aircraft fueled by Jetex take to the sky across the world. Being at the forefront of aviation fuel efficiency, Jetex is determined to reduce carbon emissions to continue developing without devaluing the environment. The new tool allows Jetex customers to calculate their flight emissions associated with the use of jet fuel and reduce them by choosing to invest in environment conservation programs. The programs are certified by international organizations such as the Verified Carbon Standard as well as Climate, Community, and Biodiversity Standard, and include protection or redevelopment of natural ecosystems "" such as forests, grasslands and wetlands "" to lower concentrations of greenhouse gases in the atmosphere. To recognize customers' input, Jetex will be issuing certificates acknowledging individual contributions.

Adel Mardini, Founder & CEO of Jetex, commented: "With private aviation growing, we are even more aware that our future has to be sustainable. Solving the complex issue of climate protection requires a multifaceted response, and offsetting emissions on flights is just one step that we are adopting to reduce our environmental impact. By working with Shell, we have carefully chosen environmental programs to ensure they are proven and deliver CO2 emissions reductions as well as benefits to the communities and local biodiversity."

"We look forward to working with Jetex to help enable their customers to compensate for flight emissions by choosing Shell's high–quality nature–based carbon offsets," said Anna Mascolo, President of Global Aviation at Shell. "Until sustainable aviation fuels and technology are developed at scale, carbon offsets will play a key role in helping the aviation sector achieve net–zero emissions."

The new service is initially offered at Dubai, Paris, Singapore, Dublin, Dusseldorf and Salalah airports, with more locations being added as more of our customers want to lead the way to fly with reduced carbon footprint.

With energy and resource conservation being at the heart of its operations, Jetex is always looking to deliver the best value to its customers globally while helping them to reduce their carbon footprint. The new carbon offset program will provide a sound foundation for further globally orchestrated and genuinely effective environmental protection measures within the private aviation sector.

– END –

About Jetex:

An award–winning global leader in executive aviation, Jetex is recognized for delivering flexible, best–in–class trip support solutions to customers worldwide. Jetex provides exceptional private terminals (FBOs), aircraft fueling, ground handling and global trip planning. The company caters to both owners and operators of business jets for corporate, commercial and personal air travel. To find out more about Jetex, visit www.jetex.com and follow us on Instagram, Twitter, Facebook, and LinkedIn.

Attachment


GLOBENEWSWIRE (Distribution ID 8158724)

Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference

PRESS RELEASE

Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference

Mont–Saint–Guibert, Belgium "" 24th February 2021 "" Nyxoah SA (Euronext: NYXH) ("Nyxoah" or the "Company"), a health–technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the participation of its management team in the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Olivier Taelman, CEO of Nyxoah, will represent the Company in a virtual session scheduled to begin at 8:40 AM (ET).

A live webcast of Nyxoah's session will be available on the Events section of the Company's investor website at https://investors.nyxoah.com/events or can be accessed via the following link:

Link to webcast

An archived replay of the presentation will be available for 90 days after the conference on Nyxoah's investor website.

– ENDS –

For further information, please contact:

Nyxoah

Milena Venkova, Corporate Communications Manager

milena.venkova@nyxoah.com

+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.

For more information, please visit www.nyxoah.com.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.


1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen–Year Follow–up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071""1078.

Attachment


GLOBENEWSWIRE (Distribution ID 1000458383)

LeddarTech Launches PixSet, the Industry’s First Full-Waveform Flash LiDAR Dataset

QUEBEC CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) — LeddarTech , a global leader in Level 1–5 ADAS and AD sensing technology, announces its first publicly available sensor dataset for advanced driver assistance and autonomous driving research and development called the Leddar PixSet. This dataset is the first of its kind in the industry to include full–waveform data from LeddarTech's Leddar Pixell, a 3D solid–state flash LiDAR sensor. LeddarTech will offer these datasets free of charge for academic and research purposes.

Sensor fusion techniques are widely used to improve the performance and robustness of computer vision algorithms. Datasets such as the Leddar PixSet allow academic and engineering research teams specializing in ADAS and AD technology to use existing sets of sensor data to test and develop advanced software and to run simulations without having to assemble new sensor suites and collect their own dataset.

An instrumented vehicle was utilized in the development of the dataset. The various scenes were recorded in high–density urban and suburban environments as well as on the highway. The data was further augmented through exposure to various weather, lighting (e.g., sunny, cloudy, rainy), and illumination (e.g., day, night, twilight) conditions. The Leddar PixSet provides information from a wide variety of situations, creating real–world data for advanced driver assistance and autonomous driving.

Dataset key features:

  • Data from an autonomous vehicle's comprehensive sensor suite
  • Includes full–waveform data from 3D solid–state flash LiDARs
  • 29k frames in 97 sequences, with more than 1.3M 3D boxes annotated
  • Various environments, weather conditions, and times of day
  • Open–source API and dataset viewer

The Leddar PixSet was developed with the collaboration of Silicon Valley–based Deepen AI, which provided comprehensive object annotations. These new datasets provide an opportunity for 3D computer vision to go beyond LiDAR point clouds with a full–waveform LiDAR dataset and are now available on the LeddarTech website.

"LeddarTech is now and has always been committed to the advancement of autonomous driving. With the release of the Leddar PixSet, we are taking one step closer to making this dream a reality. By providing these datasets free of charge to scientific and academic communities, LeddarTech is supporting and encouraging the growth and success of autonomous driving and other applications requiring LiDAR technology," stated Pierre Olivier, Chief Technology Officer of LeddarTech.

"Precisely annotated data is key in the technology development of autonomous vehicles and an important step towards achieving safer roads. Integrating Deepen's AI–powered annotation capabilities and LeddarTech environmental sensing platforms for autonomous vehicles, Leddar PixSet provides a diverse set of high–quality datasets to move the community forward," stated Mohammad Musa, Founder & CEO at Deepen AI.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end–to–end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision sensor–fusion and perception platform and its cost–effective, scalable, and versatile LiDAR development solution for automotive–grade solid–state LiDARs based on the LeddarEngine, LeddarTech enables Tier 1–2 automotive system integrators to develop full–stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting–edge automotive and mobility remote–sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice–President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1–418–653–9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

A video accompanying this release is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/fb731670–a03b–4016–abb0–defcd00472af


GLOBENEWSWIRE (Distribution ID 8158398)

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS–CoV–2 variants currently in circulation.

As the COVID–19 pandemic continues to evolve, GenMark is routinely monitoring publicly available databases for new SARS–CoV–2 strains and variants and conducting bioinformatic analyses to determine if the mutations present in the viral genome would impact detection of these variants on the ePlex RP2 Panel. The recently identified SARS–CoV–2 variant strains include multiple mutations with the majority occurring in the spike protein, or S gene region and additional mutations found in the nucleoprotein region, or N gene. The ePlex RP2 Panel targets two unique regions of the N gene; the currently identified N gene mutations for the variants listed above are found outside of the sequence region targeted by the SARS–CoV–2 assays on the ePlex RP2 Panel and therefore the following variant strains currently in circulation are predicted to be detected based on the in silico analysis: B.1.1.7 (UK), B.1.351 (South Africa) , P.1 (Brazil), COH.20G/677H and COH.20G/501Y (Ohio, USA) and B.1.429 (California, USA). GenMark will continue to update the list of variants detected by the ePlex RP2 Panel. For the most up–to date information on the SARS–CoV–2 variants detected, please visit: https://gnmk.info/SARSCoV2–Variants

The U.S. ranks 43rd in the world in sequencing of positive SARS–CoV–2 viral samples. To address this challenge, the Tracking COVID Variants Act was recently introduced with a goal to significantly boost funding and support for advanced molecular detection technologies at the Centers for Disease Control and Prevention (CDC) to provide robust genetic surveillance and sequencing activities for SARS–CoV–2 variants. GenMark joined with other members of the American Society for Microbiolgy Corporate Council in supporting this important effort to boost our nation's genomic surveillance and sequencing capacity by signing a stakeholder letter, expressing support for the bill. Specifically, the proposed bill authorizes up to $1.75 billion in emergency supplemental funding for the CDC. For more information on this important initiative: https://asm.org/Articles/Policy/2021/Feb–21/ASM–Hails–Congressional–Proposal–of–1–75–Billion–f

About the ePlex RP2 Panel

The ePlex RP2 Panel provides results for more than 20 viruses and bacteria that cause common and often serious respiratory infections, including COVID–19, flu, bronchitis, pneumonia and the common cold. With less than one minute of laboratory hands–on time and a total run time of less than two hours, the ePlex RP2 Panel is easy to use, rapid, and can be run in a broad array of hospital and reference lab settings.

The ePlex RP2 Panel helps address the double burden of this respiratory illness season by quickly identifying or ruling out the responsible pathogen(s) to enable proper treatment, potentially minimizing unnecessary use of antibiotics, which can save lives and reduce antibiotic resistance. Syndromic panels, like the ePlex RP2 Panel, allow clinicians to get the answers they need across a broad set of pathogens, enabling appropriate triage and treatment of hospitalized and critically ill patients from a single swab.

The EUA–authorized and CE–Marked ePlex RP2 Panel runs on GenMark's ePlex instrument, which is FDA cleared and CE–Marked for use with the company's ePlex RP Panel and Blood Culture Identification (BCID) Panels (Gram–positive, Gram–negative and Fungal pathogens).

About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost–of–care. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT–8 and ePlex systems are designed to support a broad range of molecular diagnostic tests with compact, easy–to–use workstations and self–contained, disposable test cartridges. GenMark's ePlex: The True Sample–to–Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.

Forward Looking Statements
This press release includes forward–looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to detect all current and future circulating SARS–CoV–2 variant strains, the continued progression of the associated public health emergency, our ability to satisfy the supply demands of our customers, and other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward–looking statements to reflect events, trends or circumstances after the date they are made.

Investor Relations Contact
Leigh Salvo
(415) 937–5404
ir@genmarkdx.com


GLOBENEWSWIRE (Distribution ID 8155975)

Sophi.io Named a WordPress VIP Featured Technology Partner

TORONTO, Feb. 18, 2021 (GLOBE NEWSWIRE) — WordPress VIP, the leading provider of enterprise WordPress, has added Sophi.io, an artificial intelligence system by The Globe and Mail, to its prestigious Technology Partnership program. Sophi joins a small group of enterprise technology companies serving VIP clients, and is the first partner to provide AI–powered automated content curation in addition to their predictive analytics and paywall solutions.

"We're excited to welcome Sophi to the growing ecosystem of enterprise integrations available to WordPress VIP customers," said Nick Gernert, CEO of WordPress VIP. "Content is the heart of enterprise growth, and our partners are key players enabling publishers and marketers to create meaningful customer experiences with powerful storytelling tools."

WordPress VIP provides a fully managed WordPress cloud platform for scale, security, performance, and flexibility, as well as end–to–end guidance and hands–on support. Some of their enterprise clients include Capgemini, Facebook, Microsoft, and News Corp, among others.

Greg Doufas, CTO at the Globe and Mail, said "We're excited to bring Sophi to all WordPress VIP users. Content publishers are exactly who Sophi was developed for. This partnership will allow Sophi to transform the way content publishers do business, and how their readers are served their most valuable content – where and how they are most receptive to it. We look forward to a strong relationship with WordPress VIP."

The award–winning Sophi suite of solutions was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions that transform their business. It is a suite of ML and NLP–powered tools that includes Sophi Automation for content curation, Sophi for Paywalls, and Sophi Analytics "" a decision–support system for publishers.

Key criteria for technology partners include clear product expertise and innovative go–to–market strategies. VIP vets every partner to identify companies with a proven track record of successful and forward thinking implementations of WordPress integration at scale.

For more information about Sophi's partnership with WordPress VIP, please visit https://wpvip.com/partner/sophi.

About Sophi.io

Sophi.io (https://www.sophi.io) was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions. It is a suite of AI–powered tools that includes Sophi Automation and Sophi for Paywalls as well as Sophi Analytics, a decision–support system for content publishers. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume. Sophi also powers automated laydown of print newspapers and ePapers.

About WordPress VIP

WordPress VIP is the leading provider of enterprise WordPress. VIP's platform provides enterprise–grade digital marketing and publishing platforms with WordPress at their core. VIP supports flagship digital marketing platforms for some of the best–known brands, including Capgemini, Hachette Book Group, and Facebook. Our digital publishing clients span the media landscape, from focused outlets such as Quartz, TechCrunch, and FiveThirtyEight to some of the biggest publishers and sites in the world, like News Corp, Rolling Stone, and Abril.

With its unparalleled power, flexibility, and interoperability, WordPress is the best digital experience solution at scale. Together with VIP's expert support, best–in–class infrastructure, and exceptional partner network, it's an unbeatable combination.


GLOBENEWSWIRE (Distribution ID 8155099)